CD19 and ovarian cancer: The proportion of CD19+CD24hiIgDlo/−CD38lo Bregs in ovarian cancer patients was comparable to that in healthy subjects, but the proportion of CD19+CD24hiIgDlo/−CD38hi Bregs in ovarian cancer patients was increased (Supplementary Fig. S12a).